Play­ing a sur­pris­ing­ly hot hand, Be­yond­Spring nails a $200M Chi­na deal in wake of a piv­otal suc­cess

Be­yond­Spring has been on a roll late­ly.

Just a few weeks ago, the New York-based biotech shocked in­vestors and an­a­lysts with how ef­fec­tive the com­pa­ny’s mol­e­cule, plinab­u­lin, was on can­cer pa­tients’ longevi­ty. Now, the biotech has forged a deal with a ma­jor play­er in the Asian mar­ket for the drug.

Be­yond­Spring an­nounced this morn­ing a com­mer­cial­iza­tion and co-de­vel­op­ment agree­ment be­tween its Chi­nese sub­sidiary Wanchun­bu­lin and Chi­na’s Jiang­su Hen­grui Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER